<DOC>
	<DOC>NCT03025945</DOC>
	<brief_summary>Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.</brief_summary>
	<brief_title>Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens. previous uveitis (&lt;1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>